fls.txt



item1.txt
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
All intercompany accounts and transactions have been eliminated in consolidation.
The accompanying Consolidated Balance Sheet as of September 30, 2017 was derived from the audited annual consolidated financial statements as of the period then ended.
Changes in estimates are recorded in the period in which they occur and become known.
Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.4 million, respectively, during the three months ended March 31, 2018 and 2017 and $2.5 million and $1.0 million, respectively, during the six months ended March 31, 2018 and 2017.
Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies.
These transactions do not qualify for hedge accounting.
Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts.
In March 2018, the FASB issued ASU No.
The guidance is effective for fiscal years beginning after December 15 2018, and interim periods within those fiscal years.
In February 2016, the FASB issued new accounting guidance for reporting lease transactions.
For finance leases, interest on a lease liability should be recognized separately from the amortization of the right-of-use asset, while for operating leases, total lease costs are recorded on a straight-line basis over the lease term.


item2.txt
Item 2.
·    Overview.
·    Critical Accounting Policies and Estimates.
anticipated or unanticipated events.
In October 2017, we acquired all of the outstanding capital stock of 4titude Limited, or 4titude, a U.K.-based manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications, for a total purchase price of $65.1 million, net of cash acquired.
Please refer to Note 4, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10‑Q for further information on this transaction.
In fiscal year 2017, we launched BioStudies, a bioinformatics sample intelligence software platform that enables customers to manage their global samples.
On April 24, 2018, the Company acquired BioSpeciMan Corporation, a Canadian provider of storage services for biological sample materials.
Gross margin was 40.6% for the second quarter of fiscal year 2018 as compared to 38.1% for the second quarter of fiscal year 2017, which resulted in an increase in gross profit of $19.7 million.
Operating expenses were $60.4 million during the second quarter of fiscal year 2018 as compared to $49.7 million during the second quarter of fiscal year 2017, an increase of $10.7 million.
Net income was $67.0 million for the three months ended March 31, 2018 as compared to $14.0 million for the corresponding period of the prior fiscal year.
The increase of $53.0 million was primarily attributable to the decrease in income taxes of $47.3 million driven by the substantial release of the tax valuation allowance of $46.2 million and an increase in operating income of $9.0 million, as noted above.
Results of Operations- Revenue for the six months ended March 31, 2018 increased to $396.6 million, or by 20%, as compared to the corresponding period of the prior fiscal year.


item3.txt
Our term loan bears variable interest rates which subjects us to interest rate risk.


item4.txt



part2.txt
Item 1A.


